Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals to Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)--Aug. 29, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells Fargo Securities 2018 Healthcare Conference on September 5, 2018 at 10:15 a.m.
View HTML
Toggle Summary Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Company Update
-- Clinical Programs Advance with CTP-543 Phase 2a Topline Data in Alopecia Areata and CTP-692 Phase 1 Trial Initiation Expected in the Fourth Quarter of 2018 -- -- Conference Call Scheduled Today at 8:30 A.M. EDT -- LEXINGTON, Mass. --(BUSINESS WIRE)--Aug. 2, 2018-- Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Concert Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018
LEXINGTON, Mass. --(BUSINESS WIRE)--Jul. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2018 financial results on Thursday, August 2, 2018 , before the U.S. financial markets open. The Company will host a conference call and webcast at
View HTML
Toggle Summary Concert Pharmaceuticals Reports First Quarter 2018 Financial Results
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass. --(BUSINESS WIRE)--May 3, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2018. “Concert has begun 2018 with strong momentum as our pipeline of first-in-class drug
View HTML
Toggle Summary Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2018 financial results on Thursday, May 3, 2018 , before the U.S. financial markets open. The Company will host a conference call and webcast at
View HTML
Toggle Summary Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
Topline Phase 2a Data from the 4 mg and 8 mg Cohorts Expected in Fourth Quarter of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Apr. 25, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the
View HTML
Toggle Summary Concert Pharmaceuticals Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 6, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Cowen 38th Annual Healthcare Conference on March 13, 2018 at 11:20 a.m.
View HTML
Toggle Summary Concert Pharmaceuticals Reports Year Ended 2017 Financial Results
CTP-543 On Track to Report Topline Phase 2a Results in Alopecia Areata by Year-End New Neuropsychiatric Product Candidate Poised to Enter Clinical Development in 2018 Conference Call Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 1, 2018-- Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia
CTP-692 Poised to Enter Clinical Development in 2018 as an Adjunctive Treatment of Schizophrenia Conference Call Scheduled Tomorrow at 8:30 a.m. ET for Company Update and 2017 Financial Results LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 28, 2018-- Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018
LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 21, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017 , on Thursday, March 1, 2018 , before the U.S. financial markets open.
View HTML